Oct. 13 (Thu.) ,2016 15:00-17:00

Annex Hall

Simultaneous Interpretation

The Facilitation of Commercialization in Various Countries and

Most of the developed countries and regions such as US, Canada, Australia also are trying to promote the R&D and the commercialization of RM products, aiming for the reduction of medical expenditures and economic growth.
In this session, lecturer from various countries and regions will give a talk on their circumstances. The lecturers from Japanese government will give explanations on the regulation of RM products, and the promotion of commercialization of RM products.


Akihiko Iwai

Vice Chairman, Forum for Innovative Regenerative Medicine / Divisional Senior Vice President, Research Portfolio & Science, Drug Discovery Research, Astellas Pharma

Understanding the Cell Therapy Manufacturing Ecosystem: Considerations for Successful Commercialization of Personalized Therapies

Phil Vanek

ARM Officer: Secretary

Advantage Australia: Cellular Therapy Commercialization Capabilities “Down Under”

Tim Oldham

AusBiotech Regenerative Medicine Advisory Group / CEO, Cell Therapies

Emily Titus

Director of Technology Development, CCRM

New Era of Regenerative Medicine

Hidetaka Nishimura

Director, Bio-Industry Division, Ministry of Economy, Trade and Industry

Close Window